References
1. Haldane V, De Foo C, Abdalla SM, et al. Health systems resilience in
managing the COVID-19 pandemic: lessons from 28 countries. Nat Med
2021;27:964-980.
2. Hemphill JC, 3rd, Greenberg SM, Anderson CS, et al. Guidelines for
the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for
Healthcare Professionals From the American Heart Association/American
Stroke Association. Stroke 2015;46:2032-2060.
3. Bauer A, Schreinlechner M, Sappler N, et al. Discontinuation versus
continuation of renin-angiotensin-system inhibitors in COVID-19
(ACEI-COVID): a prospective, parallel group, randomised, controlled,
open-label trial. Lancet Respir Med 2021.
4. Savarese G, Benson L, Sundstrom J, Lund LH. Association between
renin-angiotensin-aldosterone system inhibitor use and COVID-19
hospitalization and death: a 1.4 million patient nationwide registry
analysis. Eur J Heart Fail 2021;23:476-485.
5. Mosconi MG, Paciaroni M, Agnelli G, et al. SMASH-U classification: a
tool for aetiology-oriented management of patients with acute
haemorrhagic stroke. Intern Emerg Med 2021;16:109-114.
6. Schrag M, Kirshner H. Management of Intracerebral Hemorrhage: JACC
Focus Seminar. Journal of the American College of Cardiology
2020;75:1819-1831.
7. Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and
control of hypertension in China: data from 1.7 million adults in a
population-based screening study (China PEACE Million Persons Project).
Lancet 2017;390:2549-2558.
8. Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after
intracerebral haemorrhage: systematic review and meta-analysis. Journal
of neurology, neurosurgery, and psychiatry 2014;85:660-667.